We excluded 11.1% (156/1401) patients who had received a previous course of anti‐TNF therapy; 6.3% (88/1401) patients where a requisition error had occurred and who had never received a second anti‐TNF; 5.4% (75/1401) patients with incomplete clinical data; and 1.7% (24/1401) patients who did not have IBD. This evidence concerns the gene TNF and inflammatory bowel disease.